This site is intended for US residents aged 18 and older.

Call for more information or assistance with enrolling in Sage Central

844-4-SAGERX (844-472-4379) | M-F, 8 AM-8 PMET

Call for more information or assistance with enrolling in Sage Central

Click-to-call phone icon 844-4-SAGERX (844-472-4379) M-F, 8 AM -8 PM ET

This site is intended for US residents aged 18 and older.

Support starts here

Mom on sofa cuddling infant Mom on sofa cuddling infant

Treatment Support

Personalized support from the start

After enrolling in Sage Central, you will be connected to a Sage Central Navigator who will provide personalized patient support resources and programs for women with postpartum depression (PPD) and their families, including financial assistance programs for eligible patients, educational materials, and assistance with connecting to local resources. Our Sage Central Navigators can help you throughout your treatment journey.

Financial Assistance

We understand that paying for treatment can sometimes be challenging. That’s why Sage Central provides financial assistance options to eligible patients. Once you are enrolled in Sage Central, you will be automatically enrolled in the financial assistance programs for which you may be eligible. Your continued eligibility is subject to your satisfaction of the terms and conditions of the financial assistance programs.

  • The program is designed to help reduce a patient’s eligible out-of-pocket copay costs related to the drug. Subject to certain terms and conditions, commercially insured patients may be eligible for copay assistance to help reduce their out-of-pocket, drug-related costs up to $15,000—regardless of income level.*

    If you are eligible, the ZULRESSO Drug Copay Assistance Program will help reduce your out-of-pocket, drug-related costs for ZULRESSO up to $15,000.

    * To be eligible to participate in the ZULRESSO™ Drug Copay Assistance Program (the “Drug Copay Program”), the patient must: (i) Have private, commercial health insurance; (ii) Reside in the United States or a U.S. territory; (iii) Be treated by a healthcare professional in the United States or a U.S. territory; (iv) Be 18 years of age or older; and (v) Be prescribed ZULRESSO™ (brexanolone) injection for an on-label diagnosis. The Drug Copay Program will cover the patient’s out-of-pocket costs (i.e., deductible, copay, or coinsurance obligations) for ZULRESSO up to a maximum of $15,000. The treating healthcare provider must itemize the out-of-pocket cost for the drug on the Copay Program Reimbursement Form for the patient to be eligible to receive financial assistance under the Drug Copay Program. The patient may not participate in the Drug Copay Program if the entire cost of the patient’s ZULRESSO prescription is reimbursable by her private insurance plan or other private health or pharmacy benefit programs. The patient may not participate in the Drug Copay Program if the patient is eligible for a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). This offer is not valid for cash paying patients. The patient must deduct the value of assistance received from the Drug Copay Program from any reimbursement request submitted to her private insurance plan, either directly by the patient or on her behalf. The patient is responsible for reporting her participation in the Drug Copay Program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription. The patient should not participate in the Drug Copay Program if her insurer or health plan prohibits use of manufacturer coupons/copay assistance. The patient savings under the Drug Copay Program cannot be combined with any other savings, free trial or similar offer for the drug. Claims must be submitted in a timely manner. An Explanation of Benefits (EOB) from the patient’s private insurance must be submitted within 120 days of the date of service for the patient to receive out-of-pocket assistance. The EOB must reflect the patient’s out-of-pocket cost for ZULRESSO and submission of the claim by the patient’s physician for the cost of the medication. The Drug Copay Program is not health insurance. This offer is not conditioned on any past or future purchases. Data related to the patient’s participation in the Drug Copay Program may be collected, analyzed, and shared with Sage Therapeutics, Inc. (“Sage”) for market research and other purposes related to assessing Sage’s patient support programs. Data shared with Sage will be aggregated and de-identified; it will be combined with data related to other Copay Program use and will not identify the patient. In the event that the Drug Copay Program is terminated, the EOB must be submitted no more than 90 days after the termination date and EOB must be within the patient’s enrollment dates. Sage reserves the right to rescind, revoke or amend this offer without notice.

  • The program is designed to help reduce a patient’s eligible out-of-pocket copay costs related to the infusion. Subject to certain terms and conditions, commercially insured patients may be eligible for copay assistance to help reduce their out-of-pocket, infusion-related copay costs up to $2,000—regardless of income level.*

    (Residents of Michigan, Minnesota, Massachusetts, and Rhode Island are not eligible for infusion assistance.)

    If you are eligible, the ZULRESSO Infusion Copay Assistance Program will help reduce your out-of-pocket, infusion-related costs for ZULRESSO up to $2,000.

    * To be eligible to participate in the ZULRESSO™ Infusion Copay Assistance Program (the “Infusion Copay Program”), the patient must: (i) Have private, commercial health insurance; (ii) Reside in the United States or a U.S. territory; (iii) Be treated by a healthcare professional in the United States or a U.S. territory; (iv) Be 18 years of age or older; and (v) Be prescribed ZULRESSO™ for an on-label diagnosis. The Infusion Copay Program will cover the patients’ out-of-pocket costs (i.e., deductible, copay, or coinsurance obligations) associated with the infusion of ZULRESSO (administration, needles, tubing, infusion bags, syringes, infusion pump, preparation of medication, and IV access) up to a maximum of $2,000. The treating healthcare provider must itemize the out-of-pocket infusion costs on the Copay Program Reimbursement Form for the patient to be eligible to receive financial assistance under the Infusion Copay Program. Expenses not specifically related to the infusion of ZULRESSO are not eligible for assistance. The patient may not participate in the Infusion Copay Program if all costs of the drug infusion are reimbursable by the patient’s private insurance plan or other private health or pharmacy benefit programs. The patient may not participate in the Infusion Copay Program if the patient is eligible for a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). Residents of the following states are not eligible to participate in the Infusion Copay Program: Massachusetts, Michigan, Minnesota and Rhode Island. This offer is not valid for cash paying patients. Patient must deduct the value of assistance received from the Infusion Copay Program from any reimbursement request submitted to her private insurance plan, either directly by the patient or on her behalf. Patient is responsible for reporting her participation in the Infusion Copay Program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription. The patient should not participate in the Infusion Copay Program if her insurer or health plan prohibits use of manufacturer-supported financial assistance. Claims must be submitted in a timely manner. An Explanation of Benefits (EOB) from the patient’s private insurance must be submitted within 120 days of the date of service for the patient to receive out-of-pocket assistance. The EOB must reflect the patient’s out-of-pocket cost for infusion of ZULRESSO and submission of the claim by the patient’s physician for the infusion costs. The patient savings under the Infusion Copay Program cannot be combined with any other savings, free trial or similar offer for the drug infusion. The Infusion Copay Program is not health insurance. This offer is not conditioned on any past, present or future purchases. Data related to the patient’s participation in the Infusion Copay Program may be collected, analyzed, and shared with Sage Therapeutics, Inc. (“Sage”) for market research and other purposes related to assessing Sage’s patient support programs. Data shared with Sage will be aggregated and de-identified; it will be combined with data related to other Infusion Program use and will not identify the patient. In the event that the Infusion Copay Program is terminated, the EOB must be submitted no more than 90 days after the termination date and the EOB must be within the patient’s enrollment dates. Sage reserves the right to rescind, revoke or amend this offer without notice.

  • If you don’t have insurance or can’t afford treatment, Sage Central may be able to help.

    Speak with one of our Sage Central Navigators.

    Speak with one of our Sage Central Navigators at
    844-4-SAGERX (844-472-4379) to learn more. M-F, 8 AM -8 PM ET

Infusion Information

Getting ready for your infusion

We want you to have a positive experience during your treatment, and being prepared ahead of time can certainly help. Download this guide for some tips that may be helpful as you begin your treatment journey. You can also read the FAQs to learn more about what to expect.

Before starting treatment, talk to your doctor about the benefits and risks of ZULRESSO, and ask any questions you may have.

  • An infusion is when medicine is given directly into a vein through an IV.

  • ZULRESSO is a single IV infusion that continues over the course of 2.5 days. Because of the risk of serious harm resulting from excessive sedation or sudden loss of consciousness during treatment, ZULRESSO is only available through a restricted program called the ZULRESSO REMS in which a Healthcare Provider can carefully monitor you at a certified Healthcare Setting.

    Also, someone will need to care for your child(ren) and be in the room with you if you are with your child(ren) during the infusion.

  • Sage Central has financial assistance programs for eligible patients to help reduce the out-of-pocket costs related to your ZULRESSO treatment. Once you are enrolled in Sage Central, you will be automatically enrolled in the financial assistance programs for which you may be eligible. Your continued eligibility is subject to the satisfaction of the terms and conditions for the financial assistance program(s) in which you are enrolled. A Sage Central Navigator can help you understand your insurance and coverage options.

  • If you're considering breastfeeding while taking ZULRESSO, please talk to your doctor.

Find more support

While you’re waiting for your treatment with ZULRESSO to begin, you may want to surround yourself with additional support. Use this community resource locator tool to find community groups offering helpful resources that may be available in your area.*

If you are already an organization listed in the support locator tool and wish to opt out, please email OptOutLocatorTool@sagerx.com.

*These resources are meant to be informational only and not intended to replace medical advice. Patients should always talk to their doctor and treatment team about any medical decisions and concerns they may have. Sage Therapeutics, Inc. is not affiliated with or endorsing any particular group and we are not responsible for the content of the sites. We make no guarantees about the accuracy of the information or the quality of support provided.

What is ZULRESSO?

ZULRESSO™ (brexanolone) CIV is a prescription medicine used in adults to treat a certain type of depression called Postpartum Depression.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ZULRESSO?

ZULRESSO can cause serious side effects, including:

  • Excessive sedation and sudden loss of consciousness. ZULRESSO may cause you to feel very sleepy (excessive sedation) or pass out (loss of consciousness). Your healthcare provider should check you for symptoms of excessive sleepiness every 2 hours while you are awake
    • During your ZULRESSO infusion, tell your healthcare provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out. Your healthcare provider may lower your dose or stop the infusion until symptoms go away

    • You must have a caregiver or family member with you to help care for your child(ren) during your ZULRESSO infusion

  • Because of the risk of serious harm resulting from excessive sedation or sudden loss of consciousness, ZULRESSO is only available through a restricted program called the ZULRESSO REMS

Before receiving ZULRESSO, tell your healthcare provider about all your medical conditions, including if you:

  • drink alcohol
  • have kidney problems
  • are pregnant or think you may be pregnant. It is not known if ZULRESSO will harm your unborn baby
    • There is a pregnancy registry for females who are exposed to ZULRESSO during pregnancy. The purpose of the registry is to collect information about the health of females exposed to ZULRESSO and their baby. If you become pregnant during treatment with ZULRESSO, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visit https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/

  • are breastfeeding or plan to breastfeed. ZULRESSO passes into breast milk. Talk to your healthcare provider about the risks and benefits of breastfeeding and about the best way to feed your baby while receiving ZULRESSO

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

ZULRESSO and some medicines may interact with each other and cause serious side effects.

Especially tell your healthcare provider if you take other antidepressants, opioids, or Central Nervous System (CNS) depressants (such as benzodiazepines).

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. Your healthcare provider will decide if other medicines can be taken with ZULRESSO.

How will I receive ZULRESSO?

ZULRESSO is given to you by continuous intravenous (IV) infusion into your vein. The infusion will last for a total of 60 hours (2.5 days).

What should I avoid while receiving ZULRESSO?

  • ZULRESSO may make you feel dizzy and sleepy. Do not drive a car or do other dangerous activities after your ZULRESSO infusion until your feeling of sleepiness has completely gone away. See "What is the most important information I should know about ZULRESSO?"

  • Do not drink alcohol while receiving ZULRESSO

What are the possible side effects of ZULRESSO?

ZULRESSO can cause serious side effects, including:

  • See “What is the most important information I should know about ZULRESSO?
  • Increased risk of suicidal thoughts or actions. ZULRESSO and other antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger. Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions

How can I watch for and try to prevent suicidal thoughts and actions?

  • Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions
  • Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings
  • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms

Tell your healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:

  • Attempts to commit suicide, thoughts about suicide or dying, new or worse depression, other unusual changes in behavior or mood

The most common side effects of ZULRESSO include:

  • Sleepiness, dry mouth, passing out, flushing of the skin or face
These are not all the side effects of ZULRESSO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.